CU20200028A7 - Nucleoproteína viral y formulaciones que la contienen - Google Patents

Nucleoproteína viral y formulaciones que la contienen

Info

Publication number
CU20200028A7
CU20200028A7 CU2020000028A CU20200028A CU20200028A7 CU 20200028 A7 CU20200028 A7 CU 20200028A7 CU 2020000028 A CU2020000028 A CU 2020000028A CU 20200028 A CU20200028 A CU 20200028A CU 20200028 A7 CU20200028 A7 CU 20200028A7
Authority
CU
Cuba
Prior art keywords
nucleoprotein
rna
infectious
mass
innate immunity
Prior art date
Application number
CU2020000028A
Other languages
English (en)
Inventor
Santiago Jorge Agustín Aguiar
Rubido Julio César Aguilar
Mamun Al-Mahtab
Nieto Gerardo Enrique Guillén
Martin Kächele
Mohammad Fazle Akbar Sheikh
Frank Thiele
Helal Uddin
Maarten Van-De-Klundert
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000028A priority Critical patent/CU20200028A7/es
Priority to JP2022563491A priority patent/JP2023522118A/ja
Priority to MX2022013148A priority patent/MX2022013148A/es
Priority to CN202180043563.7A priority patent/CN115697394A/zh
Priority to PCT/CU2021/050002 priority patent/WO2021213558A2/es
Publication of CU20200028A7 publication Critical patent/CU20200028A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Nucleoproteína que comprende ácido ribonucleico (ARN) y una proteína de origen viral donde el contenido de ARN es mayor del 20 porciento (masa:masa) y dicho ARN se encuentra protegido de la degradación dentro de una estructura semejante a virus, y donde dicha nucleoproteína activa simultáneamente los receptores de la inmunidad innata TLR3, TLR2, TLR7, TLR8 y TLR9, por lo que potencia una respuesta anti-infecciosa, anti-tumoral o anti-alérgica, o activa y entrena la inmunidad innata en la prevención o tratamiento de procesos infecciosos o alérgicos. Esta nucleoproteína se puede combinarse con otros fármacos y puede aparecer como un adyuvante o un <em>carrier</em> de antígenos vacunales,en formulaciones y en un kit para su administración mucosal.</p>
CU2020000028A 2020-04-20 2020-04-20 Nucleoproteína viral y formulaciones que la contienen CU20200028A7 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CU2020000028A CU20200028A7 (es) 2020-04-20 2020-04-20 Nucleoproteína viral y formulaciones que la contienen
JP2022563491A JP2023522118A (ja) 2020-04-20 2021-04-16 ウイルス核タンパク質及びその製剤
MX2022013148A MX2022013148A (es) 2020-04-20 2021-04-16 Nucleoproteina viral y formulaciones que la contienen.
CN202180043563.7A CN115697394A (zh) 2020-04-20 2021-04-16 病毒核蛋白和包含其的制剂
PCT/CU2021/050002 WO2021213558A2 (es) 2020-04-20 2021-04-16 Nucleoproteina viral y formulaciones que la contienen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000028A CU20200028A7 (es) 2020-04-20 2020-04-20 Nucleoproteína viral y formulaciones que la contienen

Publications (1)

Publication Number Publication Date
CU20200028A7 true CU20200028A7 (es) 2021-11-04

Family

ID=77338444

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000028A CU20200028A7 (es) 2020-04-20 2020-04-20 Nucleoproteína viral y formulaciones que la contienen

Country Status (5)

Country Link
JP (1) JP2023522118A (es)
CN (1) CN115697394A (es)
CU (1) CU20200028A7 (es)
MX (1) MX2022013148A (es)
WO (1) WO2021213558A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204803D0 (en) * 2022-04-01 2022-05-18 Univ Manchester Virus-like particles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196217A1 (en) * 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
AU2010314861A1 (en) * 2009-11-09 2012-07-05 National Jewish Health Vaccine composition
US11491218B2 (en) 2016-03-31 2022-11-08 Centro De Ingeniería Genética Y Biotecnología Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus

Also Published As

Publication number Publication date
WO2021213558A2 (es) 2021-10-28
WO2021213558A3 (es) 2021-12-30
JP2023522118A (ja) 2023-05-26
MX2022013148A (es) 2022-11-16
CN115697394A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
MX2022015132A (es) Vacunas combinadas a base de acidos nucleicos.
ES2731899T3 (es) Composición de vacuna nasal contra la gripe
ES2293923T3 (es) Vacuna intranasal contra el virus influenza.
ES2562456T3 (es) Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
CN103608036B (zh) 包含菊粉颗粒的免疫佐剂组合物
JP5809560B2 (ja) インフルエンザに対して使用するためのワクチン組成物
Salleh et al. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
MX2024009845A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
KR102141887B1 (ko) 규화바이러스를 포함하는 면역성 조성물 및 사용 방법
CO6531435A2 (es) Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina
ES2340163T3 (es) Particulas similares a virosomas.
AR109538A1 (es) Vacuna contra la gripe porcina
Chen et al. Modulatory effect of CpG oligodeoxynucleotide on a DNA vaccine against nervous necrosis virus in orange-spotted grouper (Epinephelus coioides)
WO2011005772A1 (en) Methods for preparing vesicles and formulations produced therefrom
CU20200028A7 (es) Nucleoproteína viral y formulaciones que la contienen
JP2009514839A5 (es)
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
Avunje et al. Poly (I: C) and imiquimod induced immune responses and their effects on the survival of olive flounder (Paralichthys olivaceus) from viral haemorrhagic septicaemia
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR124522A1 (es) COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2
US7943147B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
UY40490A (es) Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
CN101300027B (zh) 分泌性IgA和IgG抗体诱导剂
Jiang et al. Yin L